Private equity acquires a taste for drug development
By David Carnevali (Reuters) - Private equity firms that deemed drug development too risky for their liking in the past are increasingly investing in ...
Source: whbl.com
📰 Sofinnova Partners News
Page 16 - Sofinnova Partners News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Sofinnova Partners. Real-time updates on events, politics, business and more.
Investegate |Amolyt Pharma Announcements | Amolyt Pharma: Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group
Investegate announcements from Amolyt Pharma, Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group
Source: investegate.co.uk
Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group
Funds will be used to complete phase 3 clinical development of eneboparatide (AZP-3601) for hypoparathyroidism, and advance AZP-3813 into the clinic for acromegalyLYON, France and CAMBRIDGE, Mass., Jan.
Source: finanznachrichten.de
Mission Therapeutics Successfully Completes First Clinical Assessment for Lead DUB Program, MTX652
Safety, tolerability and pharmacokinetic endpoints successfully met Follow-on clinical trials to be initiated in 2023 Mission Therapeutics ("Mission"), a drug discovery and development
United Kingdom Kostenloser Wertpapierhandel Annelize Koch Suhail Nurbhai University Of Cambridge Gurdon Institute Mission Therapeutics
Source: finanznachrichten.de
Sofinnova Partners Welcomes Mano Iyer as Venture Partner
Sofinnova Partners ("Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the appointment of Manohar (Mano) Iyer, a serial entrepreneur with
Source: finanznachrichten.de
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
MaxCyte's Flow Electroporation® and ExPERT technologies to be used to enhance Catamaran's TAILWIND® platform for novel CAR-NK cell therapies ROCKVILLE, Md, Jan. 3, 2023 /PRNewswire/
Doug Doerfler Prnewswire Maxcyte Inc Sv Health Investors Catamaran Bio Inc Flow Electroporation Catamaran Bio
Source: finanznachrichten.de
Swedish startup raises €21 million to accelerate the commercialisation of its cell-free biomanufacturing technology
EnginZyme, a green tech company developing biomanufacturing processes for the sustainable manufacturing of everyday products, announced that it had raised €21 million in a Series B financing round ...
Helen Taflin Karim Engelmark Cassimjee Alex Basu Michael Krel Technology Pioneer Royal Institute Of Technology
Source: chemeurope.com
SITRYX THERAPEUTICS ANNOUNCES PARTICIPATION AT THE LONGWOOD HEALTHCARE LEADERS PRE-JPM WEBCONFERENCE, JANUARY 5TH & JANUARY 6TH, 2023
/PRNewswire/ -- Sitryx Therapeutics Ltd (the "Company"), a biopharmaceutical company pioneering the field of immunometabolism, today announced that Neil Weir,...
Source: prnewswire.com
SITRYX THERAPEUTICS ANNOUNCES PARTICIPATION AT THE LONGWOOD HEALTHCARE LEADERS PRE-JPM WEBCONFERENCE, JANUARY 5TH & JANUARY 6TH, 2023
/PRNewswire/ -- Sitryx Therapeutics Ltd (the "Company"), a biopharmaceutical company pioneering the field of immunometabolism, today announced that Neil Weir,...
Source: prnewswire.com
May Health Completes Treatment of Five Participants in U.S. Feasibility Study of its Ovarian Rebalancing Treatment for PCOS-related Infertility
The targeted, one-time ovarian ablation procedure aims to induce ovulation for women seeking solutions for infertility related to the endocrine disorder polycystic ovary syndrome (PCOS)PARIS, FRANCE /
Source: finanznachrichten.de